This system assesses histologic lesions in chronic hepatitis C using two separate scores, one for necroinflammatory grade (A for activity) and another for the stage of fibrosis (F). These scores ...

Both obesity and type 2 diabetes can override the potential protective effect of young age on liver health, leaving this ...

Patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis who received a novel ...

and stage 4 (aHR 6.96, 95% CI 3.55–13.64) fibrosis were associated with incident liver-related events compared to stage 0–1 fibrosis. Stage 4 (aHR 8.46, 95% CI 3.26–21.99) fibrosis alone was ...

Results from a phase 2 study are also expected shortly. In MF, phase 2, stage 1 data show a decrease in bone marrow fibrosis in approximately half of patients given PRM-151 as well as an increased ...

The multicenter, randomized, double-blind ESSENCE trial (ClinicalTrial.gov Identifier: NCT04822181) included 1200 patients with MASH with moderate to advanced liver fibrosis (stage 2 or 3).

and moderate to advanced liver fibrosis (stage 2 or 3) 1. Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top ...

Sagimet Biosciences (SGMT) announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase ...

Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patientsBoth artificial ...